Collaborative Arrangements - Parion Sciences, Inc. (Details) - USD ($)		3 Months Ended
	Jun. 04, 2015	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Jun. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Indefinite-lived Intangible Assets Acquired	$ 255,300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Intangible assets				$ (284,340,000)	$ (284,340,000)
Goodwill				50,384,000	$ 50,384,000
Parion Sciences, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments		$ 5,000,000
Prior to marketing approval, time period of notice required to terminate (in days)	90 days
Subsequent to marketing approval, time period of notice required to terminate (in days)	180 days
Change of control prior to clinical trial, time period of notice required to terminate (in days)	30 days
Term of agreement following first commercial sale (in years)	10 years
Business Combination, Consideration VIE	$ 255,340,000
Milestones discount rate, low end of the range	4.10%
Milestones discount rate, high end of the range	5.90%
Commercial milestones and royalties discount rate	6.60%
Consideration paid:
Up-front payment	$ 80,000,000
Fair value of contingent payments	175,340,000
Total consideration paid	0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Consideration transferred	0
Noncontrolling interest	164,317,000
Intangible assets						$ (255,340,000)
Net other liabilities	10,468,000
Deferred tax liability	91,023,000
Goodwill	10,468,000
Parion Sciences, Inc | Enac Inhibitors in Cf
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum	490,000,000
Collaborative arrangement regulatory potential milestone payments maximum	360,000,000
Parion Sciences, Inc | Enac Inhibitors in Non Cf
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum	370,000,000
Parion Sciences, Inc | Additional Enac Inhibitors
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum	$ 230,000,000
Cystic Fibrosis Foundation Therapeutics Incorporated
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments			$ 13,900,000	$ 13,900,000